CR20130654A - 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia - Google Patents
1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofreniaInfo
- Publication number
- CR20130654A CR20130654A CR20130654A CR20130654A CR20130654A CR 20130654 A CR20130654 A CR 20130654A CR 20130654 A CR20130654 A CR 20130654A CR 20130654 A CR20130654 A CR 20130654A CR 20130654 A CR20130654 A CR 20130654A
- Authority
- CR
- Costa Rica
- Prior art keywords
- treatment
- piperazino
- deuterated
- phenyl
- indanos
- Prior art date
Links
- 201000000980 schizophrenia Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- QPABODDHXQJCDN-UHFFFAOYSA-N 1-(3-phenyl-2,3-dihydro-1h-inden-1-yl)piperazine Chemical class C12=CC=CC=C2C(C=2C=CC=CC=2)CC1N1CCNCC1 QPABODDHXQJCDN-UHFFFAOYSA-N 0.000 abstract 1
- 102000056834 5-HT2 Serotonin Receptors Human genes 0.000 abstract 1
- 108091005479 5-HT2 receptors Proteins 0.000 abstract 1
- 101150049660 DRD2 gene Proteins 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
- C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C45/00—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds
- C07C45/61—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups
- C07C45/67—Preparation of compounds having >C = O groups bound only to carbon or hydrogen atoms; Preparation of chelates of such compounds by reactions not involving the formation of >C = O groups by isomerisation; by change of size of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
La presente invención se refiere a 1-piperazino-3-fenil-indanos deuterados y sus sales con actividad en receptores dopamínicos D1 y D2, así como los receptores de 5HT2 en el sistema nervioso central, a medicamentos que comprenden tales compuestos como ingredientes activos, al uso de tales compuestos en el tratamiento de enfermedades en el sistema nervioso central y a métodos de tratamiento que comprenden la administración de tales compuestos
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161498651P | 2011-06-20 | 2011-06-20 | |
US201161537103P | 2011-09-21 | 2011-09-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
CR20130654A true CR20130654A (es) | 2014-03-24 |
Family
ID=46682855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CR20130654A CR20130654A (es) | 2011-06-20 | 2013-12-13 | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia |
Country Status (40)
Country | Link |
---|---|
US (8) | US8575174B2 (es) |
EP (4) | EP2720989B1 (es) |
JP (1) | JP5668177B2 (es) |
KR (2) | KR101879474B1 (es) |
CN (1) | CN103649019B (es) |
AP (1) | AP3310A (es) |
AR (1) | AR086987A1 (es) |
AU (1) | AU2012273657B2 (es) |
BR (1) | BR112013031702B1 (es) |
CA (1) | CA2837820C (es) |
CL (1) | CL2013003646A1 (es) |
CO (1) | CO6821965A2 (es) |
CR (1) | CR20130654A (es) |
CY (2) | CY1118158T1 (es) |
DK (2) | DK2720989T3 (es) |
DO (1) | DOP2013000305A (es) |
EA (1) | EA024651B1 (es) |
EC (1) | ECSP14013155A (es) |
ES (3) | ES2601213T3 (es) |
GE (1) | GEP201706655B (es) |
GT (1) | GT201300304A (es) |
HK (1) | HK1197228A1 (es) |
HR (2) | HRP20161348T1 (es) |
HU (2) | HUE044043T2 (es) |
IL (1) | IL229640B (es) |
JO (1) | JO3128B1 (es) |
LT (2) | LT2720989T (es) |
MA (1) | MA35268B1 (es) |
MD (1) | MD4538C1 (es) |
ME (2) | ME03375B (es) |
MX (1) | MX339552B (es) |
MY (1) | MY196998A (es) |
PE (2) | PE20150928A1 (es) |
PL (2) | PL2720989T3 (es) |
PT (2) | PT3135656T (es) |
RS (2) | RS55304B1 (es) |
SI (2) | SI3135656T1 (es) |
SM (1) | SMT201600383B (es) |
TW (3) | TWI614234B (es) |
WO (1) | WO2012176066A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PL2720989T3 (pl) | 2011-06-20 | 2017-05-31 | H. Lundbeck A/S | Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii |
AR094054A1 (es) | 2012-12-19 | 2015-07-08 | H Lundbeck As | 6-cloro-3-(fenil-d₅)-inden-1-ona y uso de la misma |
KR102638176B1 (ko) | 2017-09-07 | 2024-02-20 | 오츠카 세이야쿠 가부시키가이샤 | 중수소화-알킬을 사용하여 피페리딘 유도체 내의 피페리딘 질소를 모노-알킬화시키는 공업적 방법 |
EP3873885A1 (en) | 2018-10-29 | 2021-09-08 | H. Lundbeck A/S | Amorphous compounds of formula (i) and amorphous compounds of formula (i) salts |
JP2022509965A (ja) | 2018-12-03 | 2022-01-25 | ハー・ルンドベック・アクチエゼルスカベット | 4-((1R,3S)-6-クロロ-3-フェニル-2,3-ジヒドロ-1H-インデン-1-イル)-1,2,2-トリメチルピペラジン及び4-((1R,3S)-6-クロロ-3-(フェニル-d5)-2,3-ジヒドロ-1H-インデン-1-イル)-2,2-ジメチル-1-(メチル-d3)ピペラジンのプロドラッグ |
CA3124399A1 (en) * | 2018-12-21 | 2020-06-25 | Concert Pharmaceuticals, Inc. | Deuterated forms and derivatives of volinanserin |
CN113518771A (zh) * | 2019-03-13 | 2021-10-19 | 大塚制药株式会社 | 向含有仲胺的化合物的胺部分导入氘代低级烷基的方法 |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE50867B1 (en) | 1980-02-29 | 1986-08-06 | Kefalas As | Indane derivatives |
GB8427125D0 (en) | 1984-10-26 | 1984-12-05 | Lundbeck & Co As H | Organic compounds |
DK286990D0 (da) | 1990-12-04 | 1990-12-04 | Lundbeck & Co As H | Indanderivater |
DK55192D0 (da) | 1992-04-28 | 1992-04-28 | Lundbeck & Co As H | 1-piperazino-1,2-dihydroindenderivater |
ATE372966T1 (de) * | 1994-03-25 | 2007-09-15 | Isotechnika Inc | Verbesserung der effektivität von arzneimitteln duren deuterierung |
US6221335B1 (en) | 1994-03-25 | 2001-04-24 | Isotechnika, Inc. | Method of using deuterated calcium channel blockers |
UA81749C2 (uk) | 2001-10-04 | 2008-02-11 | Х. Луннбек А/С | Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну |
BRPI0413595B8 (pt) | 2003-08-18 | 2021-05-25 | H Lundbeck As | sal de malonato, composição farmacêutica, uso de um sal de malonato, e, método de fabricação de um composto |
MY154535A (en) * | 2003-08-18 | 2015-06-30 | Lundbeck & Co As H | Succinate and malonate salt of trans-4-((1r,3s)-6-chloro-3-phenylindan-1-y1)-1,2,2-trimethylpiperazine and the use as a medicament |
TWI376373B (en) | 2005-02-16 | 2012-11-11 | Lundbeck & Co As H | Crystalline base of a pharmaceutical compound |
TWI453198B (zh) | 2005-02-16 | 2014-09-21 | Lundbeck & Co As H | 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s)-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法 |
WO2006086985A1 (en) | 2005-02-16 | 2006-08-24 | H. Lundbeck A/S | Tartrate and malate salts of trans-1-((1r,3s)-6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine |
US7863274B2 (en) | 2005-07-29 | 2011-01-04 | Concert Pharmaceuticals Inc. | Deuterium enriched analogues of tadalafil as PDE5 inhibitors |
BRPI0615973A2 (pt) | 2005-07-29 | 2011-05-31 | Concert Pharmaceuticals Inc | novos derivados de benzo [d] [1,3] - dioxol |
EP1954669B1 (en) | 2005-12-01 | 2015-07-08 | Auspex Pharmaceuticals, Inc. | Substituted phenethylamines with serotoninergic and/or norepinephrinergic activity |
JP4986462B2 (ja) | 2006-01-27 | 2012-07-25 | シャープ株式会社 | 太陽電池ストリングおよびその製造方法、ならびに、その太陽電池ストリングを用いる太陽電池モジュール |
TW200819426A (en) | 2006-08-31 | 2008-05-01 | Lundbeck & Co As H | Novel indane compounds |
US8198305B2 (en) | 2007-04-13 | 2012-06-12 | Concert Pharmaceuticals Inc. | 1,2-benzisoxazol-3-yl compounds |
CA2686545C (en) | 2007-04-19 | 2010-11-02 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
WO2008156632A1 (en) | 2007-06-12 | 2008-12-24 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives |
US20090062303A1 (en) | 2007-08-29 | 2009-03-05 | Protia, Llc | Deuterium-enriched ziprasidone |
CN102065861B (zh) | 2008-05-07 | 2013-10-16 | H.隆德贝克有限公司 | 反式-4-((1r,3s)-6-氯-3-苯基茚满-1-基)-1,2,2-三甲基哌嗪用于改善认知的用途 |
EP2344163A1 (en) * | 2008-10-03 | 2011-07-20 | H. Lundbeck A/S | Oral formulation |
WO2010062656A2 (en) | 2008-10-28 | 2010-06-03 | Concert Pharmaceuticals Inc. | Deuterated 2-propylpentanoic acid compounds |
US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
US8658236B2 (en) * | 2009-08-21 | 2014-02-25 | Deuteria Beverages, Llc | Alcoholic compositions having a lowered risk of acetaldehydemia |
CN102020522A (zh) * | 2009-09-21 | 2011-04-20 | 陈松源 | 氘代药物的制备方法和应用 |
WO2011047315A1 (en) | 2009-10-15 | 2011-04-21 | Concert Pharmaceuticals, Inc. | Subsitituted benzimidazoles |
WO2011059080A1 (ja) * | 2009-11-16 | 2011-05-19 | 第一三共株式会社 | 同位体置換されたジアミン誘導体 |
PL2720989T3 (pl) | 2011-06-20 | 2017-05-31 | H. Lundbeck A/S | Deuterowane 1-piperazyno-3-fenyloindany do leczenia schizofrenii |
-
2012
- 2012-06-19 PL PL12748046T patent/PL2720989T3/pl unknown
- 2012-06-19 AU AU2012273657A patent/AU2012273657B2/en active Active
- 2012-06-19 JO JOP/2012/0161A patent/JO3128B1/ar active
- 2012-06-19 DK DK12748046.5T patent/DK2720989T3/en active
- 2012-06-19 RS RS20160916A patent/RS55304B1/sr unknown
- 2012-06-19 ME MEP-2019-93A patent/ME03375B/me unknown
- 2012-06-19 PE PE2015000596A patent/PE20150928A1/es active IP Right Grant
- 2012-06-19 ES ES12748046.5T patent/ES2601213T3/es active Active
- 2012-06-19 MX MX2013014849A patent/MX339552B/es active IP Right Grant
- 2012-06-19 SI SI201231582T patent/SI3135656T1/sl unknown
- 2012-06-19 GE GEAP201213350A patent/GEP201706655B/en unknown
- 2012-06-19 HU HUE16179882A patent/HUE044043T2/hu unknown
- 2012-06-19 MD MDA20140004A patent/MD4538C1/ro active IP Right Grant
- 2012-06-19 HU HUE12748046A patent/HUE030883T2/en unknown
- 2012-06-19 RS RS20190429A patent/RS58546B1/sr unknown
- 2012-06-19 EP EP12748046.5A patent/EP2720989B1/en active Active
- 2012-06-19 JP JP2014516459A patent/JP5668177B2/ja active Active
- 2012-06-19 EP EP19151618.6A patent/EP3508468B1/en active Active
- 2012-06-19 ES ES19151618T patent/ES2939477T3/es active Active
- 2012-06-19 ME MEP-2016-226A patent/ME02513B/me unknown
- 2012-06-19 EP EP23150855.7A patent/EP4215512A1/en active Pending
- 2012-06-19 AR ARP120102179 patent/AR086987A1/es active IP Right Grant
- 2012-06-19 EP EP16179882.2A patent/EP3135656B1/en active Active
- 2012-06-19 PE PE2013002857A patent/PE20141113A1/es not_active Application Discontinuation
- 2012-06-19 LT LTEP12748046.5T patent/LT2720989T/lt unknown
- 2012-06-19 AP AP2013007338A patent/AP3310A/xx active
- 2012-06-19 KR KR1020137033717A patent/KR101879474B1/ko active IP Right Grant
- 2012-06-19 EA EA201490045A patent/EA024651B1/ru not_active IP Right Cessation
- 2012-06-19 PT PT16179882T patent/PT3135656T/pt unknown
- 2012-06-19 PT PT127480465T patent/PT2720989T/pt unknown
- 2012-06-19 CA CA2837820A patent/CA2837820C/en active Active
- 2012-06-19 CN CN201280029731.8A patent/CN103649019B/zh active Active
- 2012-06-19 US US13/527,364 patent/US8575174B2/en active Active
- 2012-06-19 PL PL16179882T patent/PL3135656T3/pl unknown
- 2012-06-19 WO PCT/IB2012/001386 patent/WO2012176066A1/en active Application Filing
- 2012-06-19 LT LTEP16179882.2T patent/LT3135656T/lt unknown
- 2012-06-19 BR BR112013031702-7A patent/BR112013031702B1/pt active IP Right Grant
- 2012-06-19 DK DK16179882.2T patent/DK3135656T3/en active
- 2012-06-19 MY MYPI2021002383A patent/MY196998A/en unknown
- 2012-06-19 KR KR1020187018343A patent/KR101939546B1/ko active IP Right Grant
- 2012-06-19 ES ES16179882T patent/ES2719145T3/es active Active
- 2012-06-19 SI SI201230744A patent/SI2720989T1/sl unknown
- 2012-06-20 TW TW106107563A patent/TWI614234B/zh active
- 2012-06-20 TW TW101122028A patent/TWI627956B/zh active
- 2012-06-20 TW TW107113541A patent/TWI659741B/zh active
-
2013
- 2013-06-24 US US13/924,849 patent/US9012453B2/en active Active
- 2013-11-26 IL IL229640A patent/IL229640B/en active IP Right Grant
- 2013-12-09 GT GT201300304A patent/GT201300304A/es unknown
- 2013-12-13 CR CR20130654A patent/CR20130654A/es unknown
- 2013-12-16 DO DO2013000305A patent/DOP2013000305A/es unknown
- 2013-12-19 CO CO13296680A patent/CO6821965A2/es active IP Right Grant
- 2013-12-19 CL CL2013003646A patent/CL2013003646A1/es unknown
-
2014
- 2014-01-16 MA MA36688A patent/MA35268B1/fr unknown
- 2014-01-17 EC ECSP14013155 patent/ECSP14013155A/es unknown
- 2014-10-22 HK HK14110519A patent/HK1197228A1/zh unknown
-
2015
- 2015-03-13 US US14/656,925 patent/US9216961B2/en active Active
- 2015-11-16 US US14/941,800 patent/US9617231B2/en active Active
-
2016
- 2016-10-17 HR HRP20161348TT patent/HRP20161348T1/hr unknown
- 2016-10-26 CY CY20161101089T patent/CY1118158T1/el unknown
- 2016-10-26 SM SM201600383T patent/SMT201600383B/it unknown
-
2017
- 2017-02-17 US US15/435,826 patent/US10118907B2/en active Active
-
2018
- 2018-09-28 US US16/146,625 patent/US10501427B2/en active Active
-
2019
- 2019-03-27 HR HRP20190593TT patent/HRP20190593T1/hr unknown
- 2019-04-02 CY CY20191100368T patent/CY1121514T1/el unknown
- 2019-11-04 US US16/672,870 patent/US11059798B2/en active Active
-
2021
- 2021-06-07 US US17/340,201 patent/US20220119362A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CR20130654A (es) | 1-piperazino-3-fenil-indanos deuterados para el tratamiento de esquizofrenia | |
CO7190242A2 (es) | Moduladores del transporte nuclear y usos de los mismos | |
ECSP14013215A (es) | Compuestos novedosos | |
GT201400196A (es) | Compuestos de heterociclilo | |
CR20130371A (es) | IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS | |
UY32809A (es) | Compuestos y composiciones como inhibidores de cinasa s y k | |
CR20140032A (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido-pirimidina y su uso como modulares de receptores de c5a | |
CL2012000589A1 (es) | Compuestos derivados de pirrolo piridin carboxamidas, inhibidores de jak2; composición farmacéutica que los comprende; uso en el tratamiento de enfermedades mieloproliferativas o cáncer, tales como policitemia vera, trombocitopenia esencial, mieloma múltiple, entre otras. | |
BR112015009228A8 (pt) | Formulação farmacêutica líquida estéril e forma de dosagem intraocular oftálmica líquida estéril para injeção | |
NI201500050A (es) | Benzamidas | |
CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
NI201400003A (es) | Una nueva composición terapéutica que contiene apomorfina como ingrediente activo | |
ECSP14002542A (es) | Nuevos 2hindazoles como antagonistas del receptor ep2 | |
UY32734A (es) | Compuestos agonistas del receptor esfingosina 1-fosfato | |
ECSP13012838A (es) | Nuevos compuestos de benzodioxol-piperazina | |
ES2403549R1 (es) | Co-cristales de agomelatina con formadores de co-cristales | |
CL2015000310A1 (es) | Uso de ipidacrina para el tratamiento de los trastornos de potencia, tal como trastornos de la actividad sexual; formulacion farmaceutica que contiene ipidacrina de 3 a 300 mg. | |
TN2013000503A1 (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
ECSP099644A (es) | Derivados de quinolina, composiciones farmacéuticas que los comprenden y el uso de tales en el tratamiento de enfermedades del sistema nervioso central y periférico | |
MY166773A (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
CU20140007A7 (es) | Compuestos de tetrahidropirido-piridina y tetrahidropirido- pirimidina y su uso como moduladores de receptores de c5a | |
NI201300120A (es) | Composición farmacéutica que comprende fexofenadina | |
ECSP12012120A (es) | Compuestos de pirazol como antagonistas de crth2. |